TCEA2 (transcription elongation factor A2) is a transcription elongation factor that facilitates RNA polymerase II progression through template-encoded arresting sites during transcription 1. The protein functions by allowing cleavage of nascent transcripts to enable resumption of elongation from new 3'-termini when RNA polymerase becomes trapped in locked ternary complexes. Recent research reveals TCEA2's role in transcription-replication conflict resolution, where it is targeted for ubiquitination and removal by the CUL3-KCTD10 E3 ligase system to allow replisome bypass during co-directional conflicts 1. TCEA2 has emerged as a potential biomarker in multiple disease contexts. In chr20 kidney disease, genetically predicted TCEA2 levels show an inverse relationship with CKD risk, suggesting protective effects on kidney function 23. The protein is also implicated in cancer biology, where TCEA2 expression contributes to bortezomib resistance in t(4;14) multiple myeloma through the Aurora A-NSD2 regulatory loop 4, and knockout screens identify it as a modulator of cabazitaxel resistance in castration-resistant prostate cancer 5. Additionally, TCEA2 DNA methylation patterns may mediate intergenerational effects of maternal lifestyle factors on birth weight 6, and the protein interacts with BRCA1 in transcription-associated DNA damage responses 7.